#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=Metabolic syndrome ( MetS ) is a cluster of disorders , including insulin resistance/hyperglycemia , visceral adiposity [ identified by large waistline ( WL ) or being overweight ] , atherogenic dyslipidemia ( e. g. , raised triglycerides ( TG ) or reduced high-density lipoprotein ( HDL ) ) , and endothelial dysfunction ( characterized by elevated blood pressures ) .
3-1	17-26	Metabolic	person|abstract[4]	new|new[4]	appos|coref|appos|coref	3-4[0_4]|5-36|3-4[0_4]|5-36
3-2	27-35	syndrome	abstract[4]	new[4]	_	_
3-3	36-37	(	_	_	_	_
3-4	38-42	MetS	abstract	giv	coref	3-7[6_0]
3-5	43-44	)	_	_	_	_
3-6	45-47	is	_	_	_	_
3-7	48-49	a	abstract[6]	giv[6]	coref	4-1[0_6]
3-8	50-57	cluster	abstract[6]	giv[6]	_	_
3-9	58-60	of	abstract[6]	giv[6]	_	_
3-10	61-70	disorders	abstract[6]|abstract[7]	giv[6]|new[7]	coref	14-47[134_7]
3-11	71-72	,	abstract[6]|abstract[7]	giv[6]|new[7]	_	_
3-12	73-82	including	abstract[6]|abstract[7]	giv[6]|new[7]	_	_
3-13	83-90	insulin	abstract[6]|abstract[7]|abstract[8]	giv[6]|new[7]|new[8]	_	_
3-14	91-115	resistance/hyperglycemia	abstract[6]|abstract[7]|abstract[8]	giv[6]|new[7]|new[8]	_	_
3-15	116-117	,	abstract[6]	giv[6]	_	_
3-16	118-126	visceral	abstract[6]|abstract[9]	giv[6]|new[9]	_	_
3-17	127-136	adiposity	abstract[6]|abstract[9]	giv[6]|new[9]	_	_
3-18	137-138	[	abstract[6]	giv[6]	_	_
3-19	139-149	identified	abstract[6]	giv[6]	_	_
3-20	150-152	by	abstract[6]	giv[6]	_	_
3-21	153-158	large	abstract[6]|quantity[10]	giv[6]|new[10]	_	_
3-22	159-168	waistline	abstract[6]|quantity[10]	giv[6]|new[10]	_	_
3-23	169-170	(	abstract[6]	giv[6]	_	_
3-24	171-173	WL	abstract[6]|abstract	giv[6]|new	_	_
3-25	174-175	)	abstract[6]	giv[6]	_	_
3-26	176-178	or	abstract[6]	giv[6]	_	_
3-27	179-184	being	abstract[6]	giv[6]	_	_
3-28	185-195	overweight	abstract[6]	giv[6]	_	_
3-29	196-197	]	abstract[6]	giv[6]	_	_
3-30	198-199	,	abstract[6]	giv[6]	_	_
3-31	200-211	atherogenic	abstract[6]|abstract[12]	giv[6]|new[12]	_	_
3-32	212-224	dyslipidemia	abstract[6]|abstract[12]	giv[6]|new[12]	_	_
3-33	225-226	(	_	_	_	_
3-34	227-229	e.	_	_	_	_
3-35	230-232	g.	_	_	_	_
3-36	233-234	,	_	_	_	_
3-37	235-241	raised	_	_	_	_
3-38	242-255	triglycerides	substance	new	_	_
3-39	256-257	(	_	_	_	_
3-40	258-260	TG	abstract	new	_	_
3-41	261-262	)	_	_	_	_
3-42	263-265	or	_	_	_	_
3-43	266-273	reduced	object[15]	new[15]	appos	3-47[0_15]
3-44	274-286	high-density	object[15]	new[15]	_	_
3-45	287-298	lipoprotein	object[15]	new[15]	_	_
3-46	299-300	(	_	_	_	_
3-47	301-304	HDL	object	giv	_	_
3-48	305-306	)	_	_	_	_
3-49	307-308	)	_	_	_	_
3-50	309-310	,	_	_	_	_
3-51	311-314	and	_	_	_	_
3-52	315-326	endothelial	abstract|abstract[18]	new|new[18]	_	_
3-53	327-338	dysfunction	abstract[18]	new[18]	_	_
3-54	339-340	(	_	_	_	_
3-55	341-354	characterized	_	_	_	_
3-56	355-357	by	_	_	_	_
3-57	358-366	elevated	abstract[20]	new[20]	_	_
3-58	367-372	blood	substance|abstract[20]	new|new[20]	coref	6-14
3-59	373-382	pressures	abstract[20]	new[20]	_	_
3-60	383-384	)	_	_	_	_
3-61	385-386	.	_	_	_	_

#Text=MetS significantly influences the development and deterioration of numerous diseases and is a crucial predictor of cardiovascular diseases .
4-1	387-391	MetS	substance	giv	coref	5-13
4-2	392-405	significantly	_	_	_	_
4-3	406-416	influences	_	_	_	_
4-4	417-420	the	abstract[22]	new[22]	_	_
4-5	421-432	development	abstract[22]	new[22]	_	_
4-6	433-436	and	_	_	_	_
4-7	437-450	deterioration	abstract[23]	new[23]	_	_
4-8	451-453	of	abstract[23]	new[23]	_	_
4-9	454-462	numerous	abstract[23]|abstract[24]	new[23]|new[24]	coref	4-17[27_24]
4-10	463-471	diseases	abstract[23]|abstract[24]	new[23]|new[24]	_	_
4-11	472-475	and	_	_	_	_
4-12	476-478	is	_	_	_	_
4-13	479-480	a	abstract[25]	new[25]	ana	5-20[0_25]
4-14	481-488	crucial	abstract[25]	new[25]	_	_
4-15	489-498	predictor	abstract[25]	new[25]	_	_
4-16	499-501	of	abstract[25]	new[25]	_	_
4-17	502-516	cardiovascular	abstract[25]|abstract|abstract[27]	new[25]|new|giv[27]	coref|coref	5-39[40_27]|5-39[40_27]
4-18	517-525	diseases	abstract[25]|abstract[27]	new[25]|giv[27]	_	_
4-19	526-527	.	_	_	_	_

#Text=Fortunately , numerous modifiable risk factors and corresponding practical intervention strategies regarding MetS were proposed , and hence , it is vital to identify the high-risk individuals nowadays to prevent the incidence and deterioration of metabolic derangement and its associated diseases .
5-1	528-539	Fortunately	_	_	_	_
5-2	540-541	,	_	_	_	_
5-3	542-550	numerous	abstract[29]	new[29]	_	_
5-4	551-561	modifiable	abstract[29]	new[29]	_	_
5-5	562-566	risk	abstract|abstract[29]	new|new[29]	_	_
5-6	567-574	factors	abstract[29]	new[29]	_	_
5-7	575-578	and	_	_	_	_
5-8	579-592	corresponding	abstract[31]	new[31]	_	_
5-9	593-602	practical	abstract[31]	new[31]	_	_
5-10	603-615	intervention	event|abstract[31]	new|new[31]	_	_
5-11	616-626	strategies	abstract[31]	new[31]	_	_
5-12	627-636	regarding	_	_	_	_
5-13	637-641	MetS	abstract	giv	coref	6-10
5-14	642-646	were	_	_	_	_
5-15	647-655	proposed	_	_	_	_
5-16	656-657	,	_	_	_	_
5-17	658-661	and	_	_	_	_
5-18	662-667	hence	_	_	_	_
5-19	668-669	,	_	_	_	_
5-20	670-672	it	abstract	giv	ana	5-39
5-21	673-675	is	_	_	_	_
5-22	676-681	vital	_	_	_	_
5-23	682-684	to	_	_	_	_
5-24	685-693	identify	_	_	_	_
5-25	694-697	the	person[34]	new[34]	_	_
5-26	698-707	high-risk	person[34]	new[34]	_	_
5-27	708-719	individuals	person[34]	new[34]	_	_
5-28	720-728	nowadays	_	_	_	_
5-29	729-731	to	_	_	_	_
5-30	732-739	prevent	_	_	_	_
5-31	740-743	the	abstract[35]	new[35]	_	_
5-32	744-753	incidence	abstract[35]	new[35]	_	_
5-33	754-757	and	_	_	_	_
5-34	758-771	deterioration	abstract[36]	new[36]	_	_
5-35	772-774	of	abstract[36]	new[36]	_	_
5-36	775-784	metabolic	abstract[36]|person|abstract[38]	new[36]|giv|new[38]	_	_
5-37	785-796	derangement	abstract[36]|abstract[38]	new[36]|new[38]	_	_
5-38	797-800	and	_	_	_	_
5-39	801-804	its	abstract|abstract[40]	giv|giv[40]	_	_
5-40	805-815	associated	abstract[40]	giv[40]	_	_
5-41	816-824	diseases	abstract[40]	giv[40]	_	_
5-42	825-826	.	_	_	_	_

#Text=Nevertheless , the conventional procedures for the confirmation of MetS have depended on blood assays , which largely lead to a resistive mentality toward the procedures and are therefore nonconducive to long-term follow-up .
6-1	827-839	Nevertheless	_	_	_	_
6-2	840-841	,	_	_	_	_
6-3	842-845	the	abstract[41]	new[41]	coref	6-25[47_41]
6-4	846-858	conventional	abstract[41]	new[41]	_	_
6-5	859-869	procedures	abstract[41]	new[41]	_	_
6-6	870-873	for	abstract[41]	new[41]	_	_
6-7	874-877	the	abstract[41]|event[42]	new[41]|new[42]	_	_
6-8	878-890	confirmation	abstract[41]|event[42]	new[41]|new[42]	_	_
6-9	891-893	of	abstract[41]|event[42]	new[41]|new[42]	_	_
6-10	894-898	MetS	abstract[41]|event[42]|event	new[41]|new[42]|giv	coref	7-10
6-11	899-903	have	_	_	_	_
6-12	904-912	depended	_	_	_	_
6-13	913-915	on	_	_	_	_
6-14	916-921	blood	substance|abstract[45]	giv|new[45]	coref|coref|coref|coref	23-24|23-24[222_45]|23-24|23-24[222_45]
6-15	922-928	assays	abstract[45]	new[45]	_	_
6-16	929-930	,	_	_	_	_
6-17	931-936	which	_	_	_	_
6-18	937-944	largely	_	_	_	_
6-19	945-949	lead	_	_	_	_
6-20	950-952	to	_	_	_	_
6-21	953-954	a	abstract[46]	new[46]	_	_
6-22	955-964	resistive	abstract[46]	new[46]	_	_
6-23	965-974	mentality	abstract[46]	new[46]	_	_
6-24	975-981	toward	abstract[46]	new[46]	_	_
6-25	982-985	the	abstract[46]|abstract[47]	new[46]|giv[47]	coref	23-17[220_47]
6-26	986-996	procedures	abstract[46]|abstract[47]	new[46]|giv[47]	_	_
6-27	997-1000	and	_	_	_	_
6-28	1001-1004	are	_	_	_	_
6-29	1005-1014	therefore	_	_	_	_
6-30	1015-1027	nonconducive	_	_	_	_
6-31	1028-1030	to	_	_	_	_
6-32	1031-1040	long-term	event[48]	new[48]	_	_
6-33	1041-1050	follow-up	event[48]	new[48]	_	_
6-34	1051-1052	.	_	_	_	_

#Text=Therefore , there is a high probability of the MetS population being under-identified , especially those without an obese body shape .
7-1	1053-1062	Therefore	_	_	_	_
7-2	1063-1064	,	_	_	_	_
7-3	1065-1070	there	_	_	_	_
7-4	1071-1073	is	_	_	_	_
7-5	1074-1075	a	abstract[49]	new[49]	_	_
7-6	1076-1080	high	abstract[49]	new[49]	_	_
7-7	1081-1092	probability	abstract[49]	new[49]	_	_
7-8	1093-1095	of	abstract[49]	new[49]	_	_
7-9	1096-1099	the	abstract[49]|person[51]	new[49]|new[51]	ana	7-15[52_51]
7-10	1100-1104	MetS	abstract[49]|place|person[51]	new[49]|giv|new[51]	coref	8-18
7-11	1105-1115	population	abstract[49]|person[51]	new[49]|new[51]	_	_
7-12	1116-1121	being	_	_	_	_
7-13	1122-1138	under-identified	_	_	_	_
7-14	1139-1140	,	_	_	_	_
7-15	1141-1151	especially	person[52]	giv[52]	coref	16-23[151_52]
7-16	1152-1157	those	person[52]	giv[52]	_	_
7-17	1158-1165	without	person[52]	giv[52]	_	_
7-18	1166-1168	an	person[52]|abstract[54]	giv[52]|new[54]	_	_
7-19	1169-1174	obese	person[52]|abstract[54]	giv[52]|new[54]	_	_
7-20	1175-1179	body	person[52]|object|abstract[54]	giv[52]|new|new[54]	_	_
7-21	1180-1185	shape	person[52]|abstract[54]	giv[52]|new[54]	_	_
7-22	1186-1187	.	_	_	_	_

#Text=Consequently , there is a medical need for an easy , fast , and non-invasive method for MetS screening .
8-1	1188-1200	Consequently	_	_	_	_
8-2	1201-1202	,	_	_	_	_
8-3	1203-1208	there	_	_	_	_
8-4	1209-1211	is	_	_	_	_
8-5	1212-1213	a	abstract[55]	new[55]	_	_
8-6	1214-1221	medical	abstract[55]	new[55]	_	_
8-7	1222-1226	need	abstract[55]	new[55]	_	_
8-8	1227-1230	for	abstract[55]	new[55]	_	_
8-9	1231-1233	an	abstract[55]|abstract[56]	new[55]|new[56]	_	_
8-10	1234-1238	easy	abstract[55]|abstract[56]	new[55]|new[56]	_	_
8-11	1239-1240	,	abstract[55]|abstract[56]	new[55]|new[56]	_	_
8-12	1241-1245	fast	abstract[55]|abstract[56]	new[55]|new[56]	_	_
8-13	1246-1247	,	abstract[55]|abstract[56]	new[55]|new[56]	_	_
8-14	1248-1251	and	abstract[55]|abstract[56]	new[55]|new[56]	_	_
8-15	1252-1264	non-invasive	abstract[55]|abstract[56]	new[55]|new[56]	_	_
8-16	1265-1271	method	abstract[55]|abstract[56]	new[55]|new[56]	_	_
8-17	1272-1275	for	abstract[55]|abstract[56]	new[55]|new[56]	_	_
8-18	1276-1280	MetS	abstract[55]|abstract[56]|abstract|abstract[58]	new[55]|new[56]|giv|new[58]	coref|coref|coref|coref	15-19[141_58]|19-19[176_0]|15-19[141_58]|19-19[176_0]
8-19	1281-1290	screening	abstract[55]|abstract[56]|abstract[58]	new[55]|new[56]|new[58]	_	_
8-20	1291-1292	.	_	_	_	_

#Text=FibroScan is an ultrasound-based device equipped with the naval patented technology — Vibration-Controlled Transient Elastography ( VCTETM ) — that was originally developed to assess the level of liver fibrosis and cirrhosis by using a liver stiffness score ( the E score ) .
9-1	1293-1302	FibroScan	object	new	coref	9-3[60_0]
9-2	1303-1305	is	_	_	_	_
9-3	1306-1308	an	object[60]	giv[60]	coref	10-55[92_60]
9-4	1309-1325	ultrasound-based	object[60]	giv[60]	_	_
9-5	1326-1332	device	object[60]	giv[60]	_	_
9-6	1333-1341	equipped	_	_	_	_
9-7	1342-1346	with	_	_	_	_
9-8	1347-1350	the	abstract[61]	new[61]	appos	9-13[62_61]
9-9	1351-1356	naval	abstract[61]	new[61]	_	_
9-10	1357-1365	patented	abstract[61]	new[61]	_	_
9-11	1366-1376	technology	abstract[61]	new[61]	_	_
9-12	1377-1378	—	_	_	_	_
9-13	1379-1399	Vibration-Controlled	abstract[62]	giv[62]	_	_
9-14	1400-1409	Transient	abstract[62]|person	giv[62]|new	_	_
9-15	1410-1422	Elastography	abstract[62]	giv[62]	_	_
9-16	1423-1424	(	_	_	_	_
9-17	1425-1431	VCTETM	_	_	_	_
9-18	1432-1433	)	_	_	_	_
9-19	1434-1435	—	_	_	_	_
9-20	1436-1440	that	_	_	_	_
9-21	1441-1444	was	_	_	_	_
9-22	1445-1455	originally	_	_	_	_
9-23	1456-1465	developed	_	_	_	_
9-24	1466-1468	to	_	_	_	_
9-25	1469-1475	assess	_	_	_	_
9-26	1476-1479	the	abstract[64]	new[64]	_	_
9-27	1480-1485	level	abstract[64]	new[64]	_	_
9-28	1486-1488	of	abstract[64]	new[64]	_	_
9-29	1489-1494	liver	abstract[64]|object|object[66]	new[64]|new|new[66]	coref|coref	9-36|9-36
9-30	1495-1503	fibrosis	abstract[64]|object[66]	new[64]|new[66]	_	_
9-31	1504-1507	and	abstract[64]	new[64]	_	_
9-32	1508-1517	cirrhosis	abstract[64]|abstract	new[64]|new	_	_
9-33	1518-1520	by	_	_	_	_
9-34	1521-1526	using	_	_	_	_
9-35	1527-1528	a	abstract[70]	new[70]	appos	9-40[72_70]
9-36	1529-1534	liver	object|abstract[70]	giv|new[70]	coref	10-47
9-37	1535-1544	stiffness	abstract|abstract[70]	new|new[70]	coref	10-7[76_0]
9-38	1545-1550	score	abstract[70]	new[70]	_	_
9-39	1551-1552	(	_	_	_	_
9-40	1553-1556	the	abstract[72]	giv[72]	coref	10-14[80_72]
9-41	1557-1558	E	person|abstract[72]	new|giv[72]	coref	13-16
9-42	1559-1564	score	abstract[72]	giv[72]	_	_
9-43	1565-1566	)	_	_	_	_
9-44	1567-1568	.	_	_	_	_

#Text=Based on the transformation function of media stiffness and wave transmission velocity , the E score is calculated using a series of elastograms , which are simulated graphics of mathematical function of the time and depth of at least 10 shots of shear waves propagating through liver parenchyma transmitted using the probes mounted on the device .
10-1	1569-1574	Based	_	_	_	_
10-2	1575-1577	on	_	_	_	_
10-3	1578-1581	the	abstract[74]	new[74]	_	_
10-4	1582-1596	transformation	abstract|abstract[74]	new|new[74]	coref	11-6[95_0]
10-5	1597-1605	function	abstract[74]	new[74]	_	_
10-6	1606-1608	of	abstract[74]	new[74]	_	_
10-7	1609-1614	media	abstract[74]|abstract|abstract[76]	new[74]|new|giv[76]	_	_
10-8	1615-1624	stiffness	abstract[74]|abstract[76]	new[74]|giv[76]	_	_
10-9	1625-1628	and	abstract[74]	new[74]	_	_
10-10	1629-1633	wave	abstract[74]|abstract|abstract[79]	new[74]|new|new[79]	coref|coref	11-1[94_0]|11-1[94_0]
10-11	1634-1646	transmission	abstract[74]|abstract|abstract[79]	new[74]|new|new[79]	_	_
10-12	1647-1655	velocity	abstract[74]|abstract[79]	new[74]|new[79]	_	_
10-13	1656-1657	,	_	_	_	_
10-14	1658-1661	the	abstract[80]	giv[80]	coref	12-5[107_80]
10-15	1662-1663	E	abstract[80]	giv[80]	_	_
10-16	1664-1669	score	abstract[80]	giv[80]	_	_
10-17	1670-1672	is	_	_	_	_
10-18	1673-1683	calculated	_	_	_	_
10-19	1684-1689	using	_	_	_	_
10-20	1690-1691	a	object[81]	new[81]	_	_
10-21	1692-1698	series	object[81]	new[81]	_	_
10-22	1699-1701	of	object[81]	new[81]	_	_
10-23	1702-1713	elastograms	object[81]|abstract	new[81]|new	_	_
10-24	1714-1715	,	_	_	_	_
10-25	1716-1721	which	_	_	_	_
10-26	1722-1725	are	_	_	_	_
10-27	1726-1735	simulated	_	_	_	_
10-28	1736-1744	graphics	abstract[83]	new[83]	_	_
10-29	1745-1747	of	abstract[83]	new[83]	_	_
10-30	1748-1760	mathematical	abstract[83]|abstract[84]	new[83]|new[84]	_	_
10-31	1761-1769	function	abstract[83]|abstract[84]	new[83]|new[84]	_	_
10-32	1770-1772	of	abstract[83]|abstract[84]	new[83]|new[84]	_	_
10-33	1773-1776	the	abstract[83]|abstract[84]|time[85]	new[83]|new[84]|new[85]	_	_
10-34	1777-1781	time	abstract[83]|abstract[84]|time[85]	new[83]|new[84]|new[85]	_	_
10-35	1782-1785	and	abstract[83]|abstract[84]	new[83]|new[84]	_	_
10-36	1786-1791	depth	abstract[83]|abstract[84]|abstract	new[83]|new[84]|new	_	_
10-37	1792-1794	of	abstract[83]|abstract[84]	new[83]|new[84]	_	_
10-38	1795-1797	at	abstract[83]|abstract[84]|object[87]	new[83]|new[84]|new[87]	_	_
10-39	1798-1803	least	abstract[83]|abstract[84]|object[87]	new[83]|new[84]|new[87]	_	_
10-40	1804-1806	10	abstract[83]|abstract[84]|object[87]	new[83]|new[84]|new[87]	_	_
10-41	1807-1812	shots	abstract[83]|abstract[84]|object[87]	new[83]|new[84]|new[87]	_	_
10-42	1813-1815	of	abstract[83]|abstract[84]|object[87]	new[83]|new[84]|new[87]	_	_
10-43	1816-1821	shear	abstract[83]|abstract[84]|object[87]|abstract[88]	new[83]|new[84]|new[87]|new[88]	coref	13-10[115_88]
10-44	1822-1827	waves	abstract[83]|abstract[84]|object[87]|abstract[88]	new[83]|new[84]|new[87]|new[88]	_	_
10-45	1828-1839	propagating	_	_	_	_
10-46	1840-1847	through	_	_	_	_
10-47	1848-1853	liver	object|object[90]	giv|new[90]	coref|coref	11-23|11-23
10-48	1854-1864	parenchyma	object[90]	new[90]	_	_
10-49	1865-1876	transmitted	_	_	_	_
10-50	1877-1882	using	_	_	_	_
10-51	1883-1886	the	object[91]	new[91]	_	_
10-52	1887-1893	probes	object[91]	new[91]	_	_
10-53	1894-1901	mounted	_	_	_	_
10-54	1902-1904	on	_	_	_	_
10-55	1905-1908	the	object[92]	giv[92]	coref	14-41[0_92]
10-56	1909-1915	device	object[92]	giv[92]	_	_
10-57	1916-1917	.	_	_	_	_

#Text=The multiple-shot shear wave and elastogram transformation are implemented with controlled vibration , energy , and algorithms on the identical volume of liver tissue to ensure measurement reliability .
11-1	1918-1921	The	abstract[94]	giv[94]	_	_
11-2	1922-1935	multiple-shot	abstract[94]	giv[94]	_	_
11-3	1936-1941	shear	substance|abstract[94]	new|giv[94]	_	_
11-4	1942-1946	wave	abstract[94]	giv[94]	_	_
11-5	1947-1950	and	_	_	_	_
11-6	1951-1961	elastogram	abstract[95]	giv[95]	_	_
11-7	1962-1976	transformation	abstract[95]	giv[95]	_	_
11-8	1977-1980	are	_	_	_	_
11-9	1981-1992	implemented	_	_	_	_
11-10	1993-1997	with	_	_	_	_
11-11	1998-2008	controlled	abstract[96]	new[96]	_	_
11-12	2009-2018	vibration	abstract[96]	new[96]	_	_
11-13	2019-2020	,	_	_	_	_
11-14	2021-2027	energy	abstract	new	_	_
11-15	2028-2029	,	_	_	_	_
11-16	2030-2033	and	_	_	_	_
11-17	2034-2044	algorithms	abstract[98]	new[98]	_	_
11-18	2045-2047	on	abstract[98]	new[98]	_	_
11-19	2048-2051	the	abstract[98]|object[99]	new[98]|new[99]	_	_
11-20	2052-2061	identical	abstract[98]|object[99]	new[98]|new[99]	_	_
11-21	2062-2068	volume	abstract[98]|object[99]	new[98]|new[99]	_	_
11-22	2069-2071	of	abstract[98]|object[99]	new[98]|new[99]	_	_
11-23	2072-2077	liver	abstract[98]|object[99]|object|object[101]	new[98]|new[99]|giv|new[101]	coref|coref	12-12|12-12
11-24	2078-2084	tissue	abstract[98]|object[99]|object[101]	new[98]|new[99]|new[101]	_	_
11-25	2085-2087	to	_	_	_	_
11-26	2088-2094	ensure	_	_	_	_
11-27	2095-2106	measurement	abstract|abstract[103]	new|new[103]	coref|coref|coref|coref	13-15[118_0]|23-10[0_103]|13-15[118_0]|23-10[0_103]
11-28	2107-2118	reliability	abstract[103]	new[103]	_	_
11-29	2119-2120	.	_	_	_	_

#Text=The controlled attenuation parameter ( CAP ) score , denoting the liver steatosis , was embedded in instruments marketed after 2013 .
12-1	2121-2124	The	abstract[105]	new[105]	_	_
12-2	2125-2135	controlled	abstract[105]	new[105]	_	_
12-3	2136-2147	attenuation	abstract|abstract[105]	new|new[105]	_	_
12-4	2148-2157	parameter	abstract[105]	new[105]	_	_
12-5	2158-2159	(	abstract[107]	giv[107]	coref	13-1[112_107]
12-6	2160-2163	CAP	abstract|abstract[107]	new|giv[107]	coref	17-12
12-7	2164-2165	)	abstract[107]	giv[107]	_	_
12-8	2166-2171	score	abstract[107]	giv[107]	_	_
12-9	2172-2173	,	_	_	_	_
12-10	2174-2182	denoting	_	_	_	_
12-11	2183-2186	the	abstract[109]	new[109]	coref	17-5[154_109]
12-12	2187-2192	liver	object|abstract[109]	giv|new[109]	coref	14-49
12-13	2193-2202	steatosis	abstract[109]	new[109]	_	_
12-14	2203-2204	,	_	_	_	_
12-15	2205-2208	was	_	_	_	_
12-16	2209-2217	embedded	_	_	_	_
12-17	2218-2220	in	_	_	_	_
12-18	2221-2232	instruments	object	new	_	_
12-19	2233-2241	marketed	_	_	_	_
12-20	2242-2247	after	_	_	_	_
12-21	2248-2252	2013	time	new	_	_
12-22	2253-2254	.	_	_	_	_

#Text=The score is derived from the amplitude attenuations of ultrasonic waves detected simultaneously from the E score measurement .
13-1	2255-2258	The	abstract[112]	giv[112]	coref	13-17[0_112]
13-2	2259-2264	score	abstract[112]	giv[112]	_	_
13-3	2265-2267	is	_	_	_	_
13-4	2268-2275	derived	_	_	_	_
13-5	2276-2280	from	_	_	_	_
13-6	2281-2284	the	abstract[114]	new[114]	_	_
13-7	2285-2294	amplitude	abstract|abstract[114]	new|new[114]	_	_
13-8	2295-2307	attenuations	abstract[114]	new[114]	_	_
13-9	2308-2310	of	abstract[114]	new[114]	_	_
13-10	2311-2321	ultrasonic	abstract[114]|abstract[115]	new[114]|giv[115]	_	_
13-11	2322-2327	waves	abstract[114]|abstract[115]	new[114]|giv[115]	_	_
13-12	2328-2336	detected	_	_	_	_
13-13	2337-2351	simultaneously	_	_	_	_
13-14	2352-2356	from	_	_	_	_
13-15	2357-2360	the	abstract[118]	giv[118]	ana	14-3[0_118]
13-16	2361-2362	E	abstract|abstract[118]	giv|giv[118]	_	_
13-17	2363-2368	score	abstract|abstract[118]	giv|giv[118]	coref	17-12[158_0]
13-18	2369-2380	measurement	abstract[118]	giv[118]	_	_
13-19	2381-2382	.	_	_	_	_

#Text=Owing to its merits of being noninvasive , safe , rapid ( approximately 5 – 10 min for application ) , and the high-reproducibility of its automatically quantitative assessment outputs among operators , numerous studies have evaluated the performance of FibroScan in detecting chronic hepatitis and various other liver disorders .
14-1	2383-2388	Owing	_	_	_	_
14-2	2389-2391	to	_	_	_	_
14-3	2392-2395	its	abstract|abstract[120]	giv|new[120]	ana|coref|ana|coref	14-26|18-8[0_120]|14-26|18-8[0_120]
14-4	2396-2402	merits	abstract[120]	new[120]	_	_
14-5	2403-2405	of	_	_	_	_
14-6	2406-2411	being	_	_	_	_
14-7	2412-2423	noninvasive	_	_	_	_
14-8	2424-2425	,	_	_	_	_
14-9	2426-2430	safe	_	_	_	_
14-10	2431-2432	,	_	_	_	_
14-11	2433-2438	rapid	_	_	_	_
14-12	2439-2440	(	_	_	_	_
14-13	2441-2454	approximately	time[122]	new[122]	_	_
14-14	2455-2456	5	time[122]	new[122]	_	_
14-15	2457-2458	–	time[122]	new[122]	_	_
14-16	2459-2461	10	quantity|time[122]	new|new[122]	_	_
14-17	2462-2465	min	time[122]	new[122]	_	_
14-18	2466-2469	for	time[122]	new[122]	_	_
14-19	2470-2481	application	time[122]|abstract	new[122]|new	_	_
14-20	2482-2483	)	_	_	_	_
14-21	2484-2485	,	_	_	_	_
14-22	2486-2489	and	_	_	_	_
14-23	2490-2493	the	abstract[124]	new[124]	_	_
14-24	2494-2514	high-reproducibility	abstract[124]	new[124]	_	_
14-25	2515-2517	of	abstract[124]	new[124]	_	_
14-26	2518-2521	its	abstract[124]|abstract|abstract[127]	new[124]|giv|new[127]	_	_
14-27	2522-2535	automatically	abstract[124]|abstract[127]	new[124]|new[127]	_	_
14-28	2536-2548	quantitative	abstract[124]|abstract[127]	new[124]|new[127]	_	_
14-29	2549-2559	assessment	abstract[124]|abstract|abstract[127]	new[124]|new|new[127]	coref	18-27[166_0]
14-30	2560-2567	outputs	abstract[124]|abstract[127]	new[124]|new[127]	_	_
14-31	2568-2573	among	abstract[124]|abstract[127]	new[124]|new[127]	_	_
14-32	2574-2583	operators	abstract[124]|abstract[127]|person	new[124]|new[127]|new	_	_
14-33	2584-2585	,	_	_	_	_
14-34	2586-2594	numerous	event[129]	new[129]	coref	17-1[152_129]
14-35	2595-2602	studies	event[129]	new[129]	_	_
14-36	2603-2607	have	_	_	_	_
14-37	2608-2617	evaluated	_	_	_	_
14-38	2618-2621	the	abstract[130]	new[130]	_	_
14-39	2622-2633	performance	abstract[130]	new[130]	_	_
14-40	2634-2636	of	abstract[130]	new[130]	_	_
14-41	2637-2646	FibroScan	abstract[130]|object	new[130]|giv	coref	18-3
14-42	2647-2649	in	_	_	_	_
14-43	2650-2659	detecting	_	_	_	_
14-44	2660-2667	chronic	abstract[132]	new[132]	coref	16-6[0_132]
14-45	2668-2677	hepatitis	abstract[132]	new[132]	_	_
14-46	2678-2681	and	_	_	_	_
14-47	2682-2689	various	abstract[134]	giv[134]	coref	17-17[161_134]
14-48	2690-2695	other	abstract[134]	giv[134]	_	_
14-49	2696-2701	liver	object|abstract[134]	giv|giv[134]	coref	17-6
14-50	2702-2711	disorders	abstract[134]	giv[134]	_	_
14-51	2712-2713	.	_	_	_	_

#Text=In addition to bedside inspection in hospitalized patients , the virtue of its portability was also manifested in population outreach screening .
15-1	2714-2716	In	_	_	_	_
15-2	2717-2725	addition	_	_	_	_
15-3	2726-2728	to	_	_	_	_
15-4	2729-2736	bedside	_	_	_	_
15-5	2737-2747	inspection	event[135]	new[135]	_	_
15-6	2748-2750	in	event[135]	new[135]	_	_
15-7	2751-2763	hospitalized	event[135]|person[136]	new[135]|new[136]	coref	17-15[159_136]
15-8	2764-2772	patients	event[135]|person[136]	new[135]|new[136]	_	_
15-9	2773-2774	,	_	_	_	_
15-10	2775-2778	the	abstract[137]	new[137]	_	_
15-11	2779-2785	virtue	abstract[137]	new[137]	_	_
15-12	2786-2788	of	abstract[137]	new[137]	_	_
15-13	2789-2792	its	abstract[137]|abstract[138]	new[137]|new[138]	_	_
15-14	2793-2804	portability	abstract[137]|abstract[138]	new[137]|new[138]	_	_
15-15	2805-2808	was	_	_	_	_
15-16	2809-2813	also	_	_	_	_
15-17	2814-2824	manifested	_	_	_	_
15-18	2825-2827	in	_	_	_	_
15-19	2828-2838	population	abstract|abstract[141]	new|giv[141]	coref|coref	16-2[142_141]|16-2[142_141]
15-20	2839-2847	outreach	event|abstract[141]	new|giv[141]	_	_
15-21	2848-2857	screening	abstract[141]	giv[141]	_	_
15-22	2858-2859	.	_	_	_	_

#Text=In a street-based screening for hepatitis C virus ( HCV ) infection in drug users , the maneuver was excellently accepted by the target population .
16-1	2860-2862	In	_	_	_	_
16-2	2863-2864	a	abstract[142]	giv[142]	coref	21-12[197_142]
16-3	2865-2877	street-based	abstract[142]	giv[142]	_	_
16-4	2878-2887	screening	abstract[142]	giv[142]	_	_
16-5	2888-2891	for	abstract[142]	giv[142]	_	_
16-6	2892-2901	hepatitis	abstract[142]|abstract	giv[142]|giv	appos	16-7[144_0]
16-7	2902-2903	C	abstract[144]	giv[144]	appos	16-10[0_144]
16-8	2904-2909	virus	abstract[144]	giv[144]	_	_
16-9	2910-2911	(	_	_	_	_
16-10	2912-2915	HCV	abstract	giv	_	_
16-11	2916-2917	)	_	_	_	_
16-12	2918-2927	infection	event[146]	new[146]	_	_
16-13	2928-2930	in	event[146]	new[146]	_	_
16-14	2931-2935	drug	event[146]|substance|person[148]	new[146]|new|new[148]	_	_
16-15	2936-2941	users	event[146]|person[148]	new[146]|new[148]	_	_
16-16	2942-2943	,	_	_	_	_
16-17	2944-2947	the	event[149]	new[149]	_	_
16-18	2948-2956	maneuver	event[149]	new[149]	_	_
16-19	2957-2960	was	_	_	_	_
16-20	2961-2972	excellently	_	_	_	_
16-21	2973-2981	accepted	_	_	_	_
16-22	2982-2984	by	_	_	_	_
16-23	2985-2988	the	person[151]	giv[151]	coref	22-23[210_151]
16-24	2989-2995	target	abstract|person[151]	new|giv[151]	_	_
16-25	2996-3006	population	person[151]	giv[151]	_	_
16-26	3007-3008	.	_	_	_	_

#Text=Various studies have reported the liver steatosis grading cut-off points of CAP score in patients with different liver disorders with satisfactory accuracy .
17-1	3009-3016	Various	event[152]	giv[152]	_	_
17-2	3017-3024	studies	event[152]	giv[152]	_	_
17-3	3025-3029	have	_	_	_	_
17-4	3030-3038	reported	_	_	_	_
17-5	3039-3042	the	abstract[154]	giv[154]	coref	18-33[0_154]
17-6	3043-3048	liver	object|abstract[154]	giv|giv[154]	coref	17-18
17-7	3049-3058	steatosis	abstract[154]	giv[154]	_	_
17-8	3059-3066	grading	_	_	_	_
17-9	3067-3074	cut-off	abstract|abstract[156]	new|new[156]	_	_
17-10	3075-3081	points	abstract[156]	new[156]	_	_
17-11	3082-3084	of	abstract[156]	new[156]	_	_
17-12	3085-3088	CAP	abstract[156]|abstract|abstract[158]	new[156]|giv|giv[158]	_	_
17-13	3089-3094	score	abstract[156]|abstract[158]	new[156]|giv[158]	_	_
17-14	3095-3097	in	_	_	_	_
17-15	3098-3106	patients	person[159]	giv[159]	_	_
17-16	3107-3111	with	person[159]	giv[159]	_	_
17-17	3112-3121	different	person[159]|abstract[161]	giv[159]|giv[161]	coref	22-31[0_161]
17-18	3122-3127	liver	person[159]|object|abstract[161]	giv[159]|giv|giv[161]	coref	18-30
17-19	3128-3137	disorders	person[159]|abstract[161]	giv[159]|giv[161]	_	_
17-20	3138-3142	with	person[159]|abstract[161]	giv[159]|giv[161]	_	_
17-21	3143-3155	satisfactory	person[159]|abstract[161]|abstract[162]	giv[159]|giv[161]|new[162]	_	_
17-22	3156-3164	accuracy	person[159]|abstract[161]|abstract[162]	giv[159]|giv[161]|new[162]	_	_
17-23	3165-3166	.	_	_	_	_

#Text=Overall , FibroScan has a multitude of merits , such as being noninvasive , safe , fast , convenient , portable , and highly accurate in the assessment of liver stiffness and steatosis .
18-1	3167-3174	Overall	_	_	_	_
18-2	3175-3176	,	_	_	_	_
18-3	3177-3186	FibroScan	object	giv	coref	21-3[194_0]
18-4	3187-3190	has	_	_	_	_
18-5	3191-3192	a	abstract[164]	new[164]	_	_
18-6	3193-3202	multitude	abstract[164]	new[164]	_	_
18-7	3203-3205	of	abstract[164]	new[164]	_	_
18-8	3206-3212	merits	abstract[164]|abstract	new[164]|giv	_	_
18-9	3213-3214	,	_	_	_	_
18-10	3215-3219	such	_	_	_	_
18-11	3220-3222	as	_	_	_	_
18-12	3223-3228	being	_	_	_	_
18-13	3229-3240	noninvasive	_	_	_	_
18-14	3241-3242	,	_	_	_	_
18-15	3243-3247	safe	_	_	_	_
18-16	3248-3249	,	_	_	_	_
18-17	3250-3254	fast	_	_	_	_
18-18	3255-3256	,	_	_	_	_
18-19	3257-3267	convenient	_	_	_	_
18-20	3268-3269	,	_	_	_	_
18-21	3270-3278	portable	_	_	_	_
18-22	3279-3280	,	_	_	_	_
18-23	3281-3284	and	_	_	_	_
18-24	3285-3291	highly	_	_	_	_
18-25	3292-3300	accurate	_	_	_	_
18-26	3301-3303	in	_	_	_	_
18-27	3304-3307	the	abstract[166]	giv[166]	_	_
18-28	3308-3318	assessment	abstract[166]	giv[166]	_	_
18-29	3319-3321	of	abstract[166]	giv[166]	_	_
18-30	3322-3327	liver	abstract[166]|object|abstract[168]	giv[166]|giv|new[168]	coref|coref	19-16|19-16
18-31	3328-3337	stiffness	abstract[166]|abstract[168]	giv[166]|new[168]	_	_
18-32	3338-3341	and	abstract[166]	giv[166]	_	_
18-33	3342-3351	steatosis	abstract[166]|abstract	giv[166]|giv	coref	19-16[175_0]
18-34	3352-3353	.	_	_	_	_

#Text=A previous study found that the grades based on abdominal ultrasonography gave accurate information regarding liver steatosis and MetS in nonalcoholic , healthy people .
19-1	3354-3355	A	abstract[170]	new[170]	_	_
19-2	3356-3364	previous	abstract[170]	new[170]	_	_
19-3	3365-3370	study	abstract[170]	new[170]	_	_
19-4	3371-3376	found	_	_	_	_
19-5	3377-3381	that	_	_	_	_
19-6	3382-3385	the	abstract[171]	new[171]	_	_
19-7	3386-3392	grades	abstract[171]	new[171]	_	_
19-8	3393-3398	based	_	_	_	_
19-9	3399-3401	on	_	_	_	_
19-10	3402-3411	abdominal	object[172]	new[172]	_	_
19-11	3412-3427	ultrasonography	object[172]	new[172]	_	_
19-12	3428-3432	gave	_	_	_	_
19-13	3433-3441	accurate	abstract[173]	new[173]	_	_
19-14	3442-3453	information	abstract[173]	new[173]	_	_
19-15	3454-3463	regarding	_	_	_	_
19-16	3464-3469	liver	object|abstract[175]	giv|giv[175]	coref|coref|coref|coref	20-20|20-37[190_175]|20-20|20-37[190_175]
19-17	3470-3479	steatosis	abstract[175]	giv[175]	_	_
19-18	3480-3483	and	_	_	_	_
19-19	3484-3488	MetS	abstract[176]	giv[176]	coref	20-12[180_176]
19-20	3489-3491	in	abstract[176]	giv[176]	_	_
19-21	3492-3504	nonalcoholic	abstract[176]|person[177]	giv[176]|new[177]	coref	22-21[0_177]
19-22	3505-3506	,	abstract[176]|person[177]	giv[176]|new[177]	_	_
19-23	3507-3514	healthy	abstract[176]|person[177]	giv[176]|new[177]	_	_
19-24	3515-3521	people	abstract[176]|person[177]	giv[176]|new[177]	_	_
19-25	3522-3523	.	_	_	_	_

#Text=Moreover , considering the frequent coexistence and common pathological mechanisms of MetS and hepatopathy , such as steatohepatitis , liver inflammation , or the nonalcoholic fatty liver disease ( NAFLD ) , it was proposed that liver steatosis , especially NAFLD , could be a hepatic manifestation of MetS .
20-1	3524-3532	Moreover	_	_	_	_
20-2	3533-3534	,	_	_	_	_
20-3	3535-3546	considering	_	_	_	_
20-4	3547-3550	the	abstract[178]	new[178]	_	_
20-5	3551-3559	frequent	abstract[178]	new[178]	_	_
20-6	3560-3571	coexistence	abstract[178]	new[178]	_	_
20-7	3572-3575	and	_	_	_	_
20-8	3576-3582	common	abstract[179]	new[179]	_	_
20-9	3583-3595	pathological	abstract[179]	new[179]	_	_
20-10	3596-3606	mechanisms	abstract[179]	new[179]	_	_
20-11	3607-3609	of	abstract[179]	new[179]	_	_
20-12	3610-3614	MetS	abstract[179]|abstract[180]	new[179]|giv[180]	coref	20-49[0_180]
20-13	3615-3618	and	abstract[179]|abstract[180]	new[179]|giv[180]	_	_
20-14	3619-3630	hepatopathy	abstract[179]|abstract[180]|abstract	new[179]|giv[180]|new	_	_
20-15	3631-3632	,	abstract[179]	new[179]	_	_
20-16	3633-3637	such	abstract[179]	new[179]	_	_
20-17	3638-3640	as	abstract[179]	new[179]	_	_
20-18	3641-3656	steatohepatitis	abstract[179]|abstract	new[179]|new	_	_
20-19	3657-3658	,	abstract[179]	new[179]	_	_
20-20	3659-3664	liver	abstract[179]|object|abstract[184]	new[179]|giv|new[184]	coref|coref	20-27|20-27
20-21	3665-3677	inflammation	abstract[179]|abstract[184]	new[179]|new[184]	_	_
20-22	3678-3679	,	abstract[179]	new[179]	_	_
20-23	3680-3682	or	abstract[179]	new[179]	_	_
20-24	3683-3686	the	abstract[179]	new[179]	_	_
20-25	3687-3699	nonalcoholic	abstract[179]	new[179]	_	_
20-26	3700-3705	fatty	abstract[179]	new[179]	_	_
20-27	3706-3711	liver	abstract[179]|object|abstract[186]	new[179]|giv|new[186]	appos|coref|appos|coref	20-30[0_186]|20-37|20-30[0_186]|20-37
20-28	3712-3719	disease	abstract[179]|abstract[186]	new[179]|new[186]	_	_
20-29	3720-3721	(	_	_	_	_
20-30	3722-3727	NAFLD	abstract	giv	ana	20-33
20-31	3728-3729	)	_	_	_	_
20-32	3730-3731	,	_	_	_	_
20-33	3732-3734	it	abstract	giv	_	_
20-34	3735-3738	was	_	_	_	_
20-35	3739-3747	proposed	_	_	_	_
20-36	3748-3752	that	_	_	_	_
20-37	3753-3758	liver	object|abstract[190]	giv|giv[190]	appos|appos	20-40[191_190]|20-40[191_190]
20-38	3759-3768	steatosis	abstract[190]	giv[190]	_	_
20-39	3769-3770	,	_	_	_	_
20-40	3771-3781	especially	abstract[191]	giv[191]	coref	20-45[192_191]
20-41	3782-3787	NAFLD	abstract[191]	giv[191]	_	_
20-42	3788-3789	,	_	_	_	_
20-43	3790-3795	could	_	_	_	_
20-44	3796-3798	be	_	_	_	_
20-45	3799-3800	a	abstract[192]	giv[192]	_	_
20-46	3801-3808	hepatic	abstract[192]	giv[192]	_	_
20-47	3809-3822	manifestation	abstract[192]	giv[192]	_	_
20-48	3823-3825	of	abstract[192]	giv[192]	_	_
20-49	3826-3830	MetS	abstract[192]|abstract	giv[192]|giv	coref	21-16
20-50	3831-3832	.	_	_	_	_

#Text=Therefore , the FibroScan is investigated to be an option for the frontline screening of MetS in participants of a self-paid health examination in Taiwan .
21-1	3833-3842	Therefore	_	_	_	_
21-2	3843-3844	,	_	_	_	_
21-3	3845-3848	the	object[194]	giv[194]	coref	22-18[0_194]
21-4	3849-3858	FibroScan	object[194]	giv[194]	_	_
21-5	3859-3861	is	_	_	_	_
21-6	3862-3874	investigated	_	_	_	_
21-7	3875-3877	to	_	_	_	_
21-8	3878-3880	be	_	_	_	_
21-9	3881-3883	an	abstract[195]	new[195]	_	_
21-10	3884-3890	option	abstract[195]	new[195]	_	_
21-11	3891-3894	for	abstract[195]	new[195]	_	_
21-12	3895-3898	the	abstract[195]|abstract[197]	new[195]|giv[197]	_	_
21-13	3899-3908	frontline	abstract[195]|organization|abstract[197]	new[195]|new|giv[197]	_	_
21-14	3909-3918	screening	abstract[195]|abstract[197]	new[195]|giv[197]	_	_
21-15	3919-3921	of	abstract[195]|abstract[197]	new[195]|giv[197]	_	_
21-16	3922-3926	MetS	abstract[195]|abstract[197]|object	new[195]|giv[197]|giv	coref	22-35
21-17	3927-3929	in	abstract[195]	new[195]	_	_
21-18	3930-3942	participants	abstract[195]|person[199]	new[195]|new[199]	_	_
21-19	3943-3945	of	abstract[195]|person[199]	new[195]|new[199]	_	_
21-20	3946-3947	a	abstract[195]|person[199]|event[201]	new[195]|new[199]|new[201]	_	_
21-21	3948-3957	self-paid	abstract[195]|person[199]|event[201]	new[195]|new[199]|new[201]	_	_
21-22	3958-3964	health	abstract[195]|person[199]|abstract|event[201]	new[195]|new[199]|new|new[201]	_	_
21-23	3965-3976	examination	abstract[195]|person[199]|event[201]	new[195]|new[199]|new[201]	_	_
21-24	3977-3979	in	abstract[195]|person[199]|event[201]	new[195]|new[199]|new[201]	_	_
21-25	3980-3986	Taiwan	abstract[195]|person[199]|event[201]|place	new[195]|new[199]|new[201]|new	_	_
21-26	3987-3988	.	_	_	_	_

#Text=To the best of our knowledge , this is the first study to explore the utility of FibroScan in identifying people from the general population who have physical status and disorders that fulfill the MetS criteria .
22-1	3989-3991	To	_	_	_	_
22-2	3992-3995	the	_	_	_	_
22-3	3996-4000	best	_	_	_	_
22-4	4001-4003	of	_	_	_	_
22-5	4004-4007	our	person|abstract[204]	acc|new[204]	ana|ana	22-8[0_204]|22-8[0_204]
22-6	4008-4017	knowledge	abstract[204]	new[204]	_	_
22-7	4018-4019	,	_	_	_	_
22-8	4020-4024	this	abstract	giv	coref	22-10[206_0]
22-9	4025-4027	is	_	_	_	_
22-10	4028-4031	the	abstract[206]	giv[206]	_	_
22-11	4032-4037	first	abstract[206]	giv[206]	_	_
22-12	4038-4043	study	abstract[206]	giv[206]	_	_
22-13	4044-4046	to	_	_	_	_
22-14	4047-4054	explore	_	_	_	_
22-15	4055-4058	the	abstract[207]	new[207]	_	_
22-16	4059-4066	utility	abstract[207]	new[207]	_	_
22-17	4067-4069	of	abstract[207]	new[207]	_	_
22-18	4070-4079	FibroScan	abstract[207]|object	new[207]|giv	_	_
22-19	4080-4082	in	_	_	_	_
22-20	4083-4094	identifying	_	_	_	_
22-21	4095-4101	people	person	giv	_	_
22-22	4102-4106	from	_	_	_	_
22-23	4107-4110	the	person[210]	giv[210]	_	_
22-24	4111-4118	general	person[210]	giv[210]	_	_
22-25	4119-4129	population	person[210]	giv[210]	_	_
22-26	4130-4133	who	_	_	_	_
22-27	4134-4138	have	_	_	_	_
22-28	4139-4147	physical	abstract[211]	new[211]	_	_
22-29	4148-4154	status	abstract[211]	new[211]	_	_
22-30	4155-4158	and	_	_	_	_
22-31	4159-4168	disorders	abstract	giv	_	_
22-32	4169-4173	that	_	_	_	_
22-33	4174-4181	fulfill	_	_	_	_
22-34	4182-4185	the	abstract[214]	new[214]	_	_
22-35	4186-4190	MetS	abstract|abstract[214]	giv|new[214]	coref	23-14
22-36	4191-4199	criteria	abstract[214]	new[214]	_	_
22-37	4200-4201	.	_	_	_	_

#Text=A subsequent objective was to explore its feasibility and reliability in screening for MetS without performing any simultaneous invasive procedures , such as blood assays .
23-1	4202-4203	A	abstract[215]	new[215]	ana	23-7[0_215]
23-2	4204-4214	subsequent	abstract[215]	new[215]	_	_
23-3	4215-4224	objective	abstract[215]	new[215]	_	_
23-4	4225-4228	was	_	_	_	_
23-5	4229-4231	to	_	_	_	_
23-6	4232-4239	explore	_	_	_	_
23-7	4240-4243	its	abstract|abstract[217]	giv|new[217]	_	_
23-8	4244-4255	feasibility	abstract[217]	new[217]	_	_
23-9	4256-4259	and	_	_	_	_
23-10	4260-4271	reliability	abstract	giv	_	_
23-11	4272-4274	in	_	_	_	_
23-12	4275-4284	screening	_	_	_	_
23-13	4285-4288	for	_	_	_	_
23-14	4289-4293	MetS	object	giv	_	_
23-15	4294-4301	without	_	_	_	_
23-16	4302-4312	performing	_	_	_	_
23-17	4313-4316	any	abstract[220]	giv[220]	_	_
23-18	4317-4329	simultaneous	abstract[220]	giv[220]	_	_
23-19	4330-4338	invasive	abstract[220]	giv[220]	_	_
23-20	4339-4349	procedures	abstract[220]	giv[220]	_	_
23-21	4350-4351	,	abstract[220]	giv[220]	_	_
23-22	4352-4356	such	abstract[220]	giv[220]	_	_
23-23	4357-4359	as	abstract[220]	giv[220]	_	_
23-24	4360-4365	blood	abstract[220]|substance|abstract[222]	giv[220]|giv|giv[222]	_	_
23-25	4366-4372	assays	abstract[220]|abstract[222]	giv[220]|giv[222]	_	_
23-26	4373-4374	.	_	_	_	_
